Controlling costs in the intensive-care unit: role of daily microbiologist rounds in an Indian hospital  by Kothari, A. et al.
CORRESPONDENCE
Controlling costs in the intensive-care unit:
role of daily microbiologist rounds in an
Indian hospital
10.1111/j.1469-0691.2008.02109.x
Hadi et al. [1] recently reported in CMI an audit of
antibiotic prescribing practice in two teaching
hospitals in Indonesia. In this study, 84% of
patients had received an antibiotic during hospi-
talization, of whom only 21% were considered to
have been truly appropriately treated. Spiralling
costs of both procedures and drugs have led to an
increasing emphasis on control of expense in
hospitals, with a special focus on intensive-care
units (ICUs). Historically, antimicrobial control
policies have been used to control costs, with a
side beneﬁt of reduced selective pressure and,
thus, less antimicrobial resistance.
We report our experience in India of the impact
of daily rounds made by a clinical microbiologist
to assess antibiotic consumption patterns in an
ICU. This was a retrospective analysis, in a
cardiothoracic surgical ICU, of the consumption
of expensive, broad-spectrum antibiotics.
Data regarding the use of antimicrobial agents
before (January–February 2005) and after (March–
December 2005) the introduction of clinical micro-
biologist rounds were analysed. Deﬁned daily
doses (DDD) per 1000 patient bed-days were
calculated for carbapenems, antipseudomonal
penicillins, glycopeptides and third-generation
cephalosporins according to the National Noso-
comial Infections Surveillance deﬁnitions [2].
Drug acquisition costs were used to calculate
antibiotic cost (in US dollars (USD)) per patient-
day in the ICU. The statistical signiﬁcance of the
difference between the two sets of data was
calculated using the unpaired t-test.
The DDD per 1000 patient bed-days during the
period before the introduction of clinical micro-
biologist rounds was 146.4 for carbapenems, 308.1
for antipseudomonal penicillins, 127.8 for glyco-
peptides, and 235.2 for third-generation ceph-
alosporins. After the introduction of clinical
microbiologist rounds, the DDD per 1000 patient
bed-days was 35.6 (p 0.0153) for carbapenems,
150.9 (p 0.0137) for antipseudomonal penicillins,
140.4 (p 0.78) for glycopeptides, and 119.5 (p 0.3)
for third-generation cephalosporins. The antibiotic
cost per patient-day was reduced from 48.5 USD
before the introduction of clinical microbiologist
rounds to 20.6 USD in the subsequent period
(p 0.0023). Sepsis-associated morbidity and mor-
tality did not change during the same period.
There was then a signiﬁcant decrease in the
costs associated with antibiotic use after the
introduction of clinical microbiologist rounds in
the ICU. Studies have demonstrated that at least
one-third of all hospitalized patients receive a
course of antimicrobial therapy, and that approx-
imately 50% of these prescriptions are unneces-
sary or otherwise inappropriate [3]. Antibiotic
expenditures can account for as much as 30–50%
of a hospital’s total drug budget [4]. Among the
unwanted consequences of antimicrobial therapy
are adverse reactions, the emergence of drug-
resistant microorganisms, predisposition to sec-
ondary infections, and the increased cost of
medical care [5].
With the widespread emergence of resistance in
microorganisms [6], and the rising costs of anti-
microbial agents, it is essential to develop local
antimicrobial management strategies in India. As
India has a dearth of trained infectious diseases
specialists and clinical pharmacists, all antimicro-
bial stewardship strategies in hospitals have to be
driven by clinical microbiologists. Our experi-
ence, which is based on a novel experiment in
India, shows that daily clinical microbiologist
rounds contributed to optimizing the antibiotic
therapy regimens, reducing the cost of therapy
with no adverse impact on rates of morbidity
and mortality due to sepsis during the same
period.
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Human parvovirus B19 (B19) is a common infec-
tious pathogen in humans [1]. Since its discovery,
B19 has been linked with a broad spectrum of
clinical syndromes. An aetiological role of the
virus has been conﬁrmed in erythema infection,
transient aplastic crisis, persistent infection man-
ifesting as pure red cell aplasia in immunocom-
promised persons, non-immune hydrops fetalis
and arthritis. Less commonly recognized, but
receiving increasing attention, are the neurolog-
ical manifestations, a variety of which have been
described in patients with either clinically
diagnosed or laboratory-conﬁrmed B19 infection
[2].
Meningoencephalitis due to B19 in adults is a
rare entity and, to our knowledge, only several
cases have been reported in the literature [3–7]
(Table 1). We describe here a case of aseptic
meningoencephalitis caused by B19 in an immu-
nocompetent patient who had predominating
psychiatric symptoms.
A 75-year-old, previously healthy retired doc-
tor was admitted to hospital because of abrupt
onset of headache, confusion, agitation, dysar-
thria and fever. Physical examination revealed
apparent neck stiffness. The initial fever was
c. 38C and resolved in 2 days. Psychiatric exam-
ination revealed confusion, irritability, agitation,
disorientation, language disturbance, difﬁculty in
object naming, mood swings, persecutory delu-
sions and delusions of inﬂuence, tactile and visual
hallucinations and increasedpsychomotor activity.
The patient displayed sudden impairment of
attention-focus, perception and cognition, and
disturbance of consciousness. These may have
resulted from the direct invasion of the central
nervous system by B19 or from indirect effects of
the immune response to the infection.
Routine laboratory ﬁndings (biochemistry, clin-
ical haematology and urine analysis) were nor-
mal. The values for peripheral blood leukocytes,
erythrocyte sedimentation rate and C-reactive
protein level were normal. Analysis of cerebro-
spinal ﬂuid (CSF) obtained by lumbar puncture at
high opening pressure showed a xanthochromic
appearance, an elevated white blood cell count
(210 ⁄mm3) with a predominance of lymphocytes
(95%), and increased total protein (242 mg ⁄dL)
and glucose levels (74 mg ⁄dL; simultaneous
blood glucose level, 120 mg ⁄dL). Microbiological
assays and repeated cultures of blood and CSF
did not reveal any bacterial, fungal or parasitic
infection. Tuberculosis was ruled out on the basis
of negative PCR results and the repeated absence
of Mycobacterium tuberculosis, after Ziehl–Nielsen
staining and 8 weeks of culture on Lo¨wenstein–
Jensen medium.
Magnetic resonance imaging did not show any
cerebral or cerebellar abnormalities, apart from
Table 1. Clinical and laboratory characteristics of documented cases of adult meningoencephalitis associated with
infection due to parvovirus B19
Reference Age (years) ⁄ sex
B19-related symptoms
Sequela ⁄death
B19 markers in serum B19 markers in CSF
Rash Anaemia Arthralgia IgM IgG DNA IgM IgG DNA
[3] 35 ⁄M ) + ) ) ⁄) + + + ND ND +
[4] 26 ⁄ F ) + ) ) ⁄+ + + + ND ND +
[5] 17 ⁄ F ) ) ) ) ⁄) + + ) ND ND +
[6] 67 ⁄ F ) + ) ) ⁄) ) + ) ) + +
[7] 58 ⁄ F ) ) ) ) ⁄+ + + ) ) + +
PR 75 ⁄M ) ) ) ) ⁄) ) + ) ) ) +a
CSF, cerebrospinal ﬂuid; PR, present report; M male; F, female; ND, not done.
a103 copies ⁄mL.
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